A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors-Reference-Cited by-同舟云学术

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

Published:2019-12-18 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Pérez-Pena Javier,Tibor Fekete Janos,Páez Raquel,Baliu-Piqué Mariona,García-Saenz José Ángel,García-Barberán Vanesa,Manzano Aránzazu,Pérez-Segura Pedro,Esparis-Ogando Azucena,Pandiella Atanasio,Gyorffy Balázs,Ocana Alberto

Funder

Instituto de Salud Carlos III

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference24 articles.

1. Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options;Ocana;Clin Cancer Res.,2008

2. Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies;Ocana;Oncotarget.,2017

3. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance;Ocana;Am J Clin Oncol.,2006

4. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med.,2018

5. Cancer immunotherapy using checkpoint blockade;Ribas;Science,2018

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy;Cancer Reports;2024-03

2. MDR1-expressing CD4⁺T cells with Th1.17 features resist to neoadjuvant chemotherapy and are associated with breast cancer clinical response;Journal for ImmunoTherapy of Cancer;2023-11

3. Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy;Frontiers in Oncology;2023-05-22

4. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer;Nature Communications;2023-04-18

5. Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy;Cancers;2023-04-07